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INTEGRATION OF BIOPROCESS DESIGN WITH TRANSCRIPTOMIC AND METABOLOMIC
CHARACTERIZATION FOR THE EXPANSION OF HUMAN PLURIPOTENT STEM CELLS
Marta M. Silva, iBET and ITQB-UNL
Apartado 12, Oeiras, Portugal
T: +351 21 446 94 32, marta.silva@itqb.unl.pt
AF Rodrigues, C Correia, MFQ Sousa, C Brito, AS Coroadinha, M Serra and PM Alves, iBET and ITQB-UNL

Human pluripotent stem cells (hPSC), including human embryonic stem cells (hESC), have an enormous potential
as source for cell replacement therapies. However, the clinical application of hPSC has been hindered by the lack
of robust protocols able to sustain production of high cell numbers maintaining their phenotype. To facilitate the
bioprocess optimization aiming at higher cell yields, the analysis of transcriptomic and metabolomic profiling would
provide important insights about stem cell phenotype in different culture conditions. Within this context, we
developed a robust and well-characterized bioprocess for hESC expansion under fully defined conditions using
stirred-tank bioreactors. Moreover, we explored the potential of transcriptomic and metabolomic tools for a more
comprehensive assessment of culture system impact on cell proliferation, metabolism, and phenotype.
In this study two hESC lines displaying different growth characteristics: a feeder-dependent hESC line (growing
as a colony) and a feeder-free hESC line (growing as a monolayer) (both from Cellectis Bioresearch) were cultured
on different synthetic microcarriers (kindly provided by Corning Inc.) in stirred-tank bioreactors. Cell growth profile
of all cultures was monitored daily and the undifferentiated phenotype was characterized by immunofluorescence
microscopy, flow cytometry, RT-qPCR and in vitro pluripotency assays. Finally, both transcriptional and metabolic
profiles of hESC cultured in stirred-tank bioreactors were analyzed and compared to the culture in 2-dimensional
(2D) monolayer system.
Our results showed the efficiency of Synthemax-II polystyrene microcarriers to expand both hESC lines in stirredtank bioreactors, with high viable cell recovery yields. Both hESC lines maintained the expression of stemness
markers and presented high pluripotency scores (according to the PluriTest bioinformatic platform), showing
similar values compared with 2D culture. Transcriptome signatures of both hESC lines were compared during the
expansion process, showing clear convergence of hESCs when cultured on synthetic microcarriers using stirred
culture systems. The most significant changes steering this convergence, were found at the level of central carbon
metabolism and cytoskeleton and extracellular matrix rearrangements. Under low-oxygen tension, hESCs
displayed a metabolic rearrangement with upregulation of the glycolytic machinery favoring an anaerobic
glycolysis Warburg-effect-like phenotype, with no evidence of hypoxic stress response, in contrast to 2D culture
[1]. This study provided relevant findings on the hESC physiological and metabolic changes during expansion,
which can contribute to the design of improved scale-up production strategies as well as for media optimization
to generate cells in higher quantity with improved quality, critical for their translation into clinic.
References: [1] Silva MM, et al. Stem Cells Transl Med. 2015;4(7):731-42.
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